Stevens-Johnson syndrome (SJS) is a rare, life-threatening reaction triggered by medications or infections. It starts with flu-like symptoms before rapidly progressing to a painful rash, skin blistering, and the detachment of the top layer of skin and mucous membranes. Because it mimics severe burns, it requires emergency medical care in a burn unit or intensive care unit. Recognizing the early warning signs and immediately stopping the offending drug are the most critical factors in patient survival.
While anyone can develop this condition, certain genetic markers and specific classes of medications elevate the risk. Understanding how the immune system misinterprets drug compounds can help clinicians spot the danger signs before permanent damage occurs to the skin, eyes, and internal organs.
What Triggers Stevens-Johnson Syndrome?
The condition typically begins as an immune system hypersensitivity reaction, usually provoked by prescription or over-the-counter medications. Rather than a direct toxic effect of the drug, the reaction stems from an abnormal immune response where T-cells attack normal skin and mucosal cells.
Common pharmaceutical triggers include:
- Anti-gout medications such as allopurinol
- Seizure medications and anticonvulsants like carbamazepine and phenytoin
- Antibiotics, particularly sulfonamides
- Pain relievers and nonsteroidal anti-inflammatory drugs (NSAIDs) like ibuprofen
Genetics play a major role in susceptibility. For instance, specific human leukocyte antigen variants, such as HLA-B*15:02, strongly predispose individuals of Asian descent to severe reactions when taking certain anticonvulsants. In rare cases, infections like Mycoplasma pneumoniae can also trigger the cascade.
Recognizing Early Symptoms and Warning Signs
The initial phase of SJS often fools both patients and general practitioners because it resembles a common viral infection. Patients experience a prodrome lasting one to three days before skin changes appear.
Early warning signs include:
- High fever, persistent fatigue, and body aches
- Sore throat, burning eyes, and a general feeling of severe illness
- Painful red or purplish macules that spread rapidly across the face and trunk
- Blisters forming on the skin and inside the mouth, nose, eyes, and genital tract
As the condition advances, the epidermis separates from the dermis with minimal friction, a phenomenon known as Nikolsky's sign. The loss of skin barrier protection leads to severe fluid loss, electrolyte imbalances, and high vulnerability to secondary bacterial infections like sepsis.
Emergency Treatment and Supportive Care
Managing SJS requires immediate hospitalization, frequently within an intensive care unit or specialized burn unit. Every hour counts when trying to halt tissue destruction.
The primary steps in clinical management include:
- Immediate Withdrawal: Discontinuing every suspected medication instantly, as prolonged exposure worsens the prognosis.
- Supportive Care: Maintaining fluid and electrolyte balance via intravenous lines, managing pain with specialized burn protocols, and providing nutritional support.
- Wound Management: Protecting exposed areas with specialized dressings that minimize trauma and prevent infection without adhesive stripping.
- Ophthalmological Care: Preventing permanent corneal scarring and blindness through frequent eye lubrication, lysis of adhesions, and topical medications.
While supportive care remains the bedrock of recovery, specialists sometimes use immunomodulating therapies such as intravenous immunoglobulin (IVIG) or cyclosporine to suppress the destructive inflammatory cascade. The National Institutes of Health provide ongoing clinical guidance on managing severe cutaneous adverse reactions.
Common Mistakes in Early Assessment
Misdiagnosing SJS during its initial stages remains a dangerous trap in emergency medicine. Clinicians sometimes mistake the prodromal phase for a routine upper respiratory infection or a mild drug allergy, leading to continued administration of the offending medication. Another frequent error is delaying transfer to a specialized burn or intensive care center while waiting for definitive biopsy results. Immediate withdrawal of the causative agent must never wait for pathology confirmation if clinical suspicion is high.
Frequently Asked Questions
How is SJS different from toxic epidermal necrolysis?
Toxic epidermal necrolysis (TEN) is part of the same disease spectrum but is far more extensive. While SJS involves skin detachment affecting less than 10 percent of the body's surface area, TEN affects more than 30 percent, carrying a significantly higher mortality rate.
Can SJS recur if I take the same medication again?
Yes. Re-exposure to the offending drug or a chemically similar medication will almost always trigger a recurrence, typically with an even faster and more severe onset. Patients must maintain a permanent record of their trigger drug.
What are the long-term complications after recovery?
Many survivors experience lasting health issues, including chronic dry eyes, visual impairments, skin pigmentation changes, scarring, dental problems, and chronic fatigue or psychological distress similar to post-traumatic stress disorder. The American Academy of Dermatology offers patient support resources for managing long-term cutaneous recovery.
Is genetic testing available to prevent SJS?
Genetic screening for specific alleles like HLA-B*15:02 is recommended before prescribing certain medications, such as carbamazepine, in high-risk populations to screen out individuals prone to severe immune hypersensitivity.
